These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
497 related items for PubMed ID: 9284735
1. Dissociation between the effects of somatostatin (SS) and octapeptide SS-analogs on hormone release in a small subgroup of pituitary- and islet cell tumors. Hofland LJ, De Herder WW, Visser-Wisselaar HA, Van Uffelen C, Waaijers M, Zuyderwijk J, Uitterlinden P, Kros MJ, Van Koetsveld PM, Lamberts SW. J Clin Endocrinol Metab; 1997 Sep; 82(9):3011-8. PubMed ID: 9284735 [Abstract] [Full Text] [Related]
2. Relative potencies of the somatostatin analogs octreotide, BIM-23014, and RC-160 on the inhibition of hormone release by cultured human endocrine tumor cells and normal rat anterior pituitary cells. Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Lamberts SW. Endocrinology; 1994 Jan; 134(1):301-6. PubMed ID: 7903931 [Abstract] [Full Text] [Related]
3. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary somatotroph adenoma cells. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. J Clin Endocrinol Metab; 2002 Dec; 87(12):5545-52. PubMed ID: 12466351 [Abstract] [Full Text] [Related]
4. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormone- and prolactin-secreting pituitary adenomas in vitro. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ, Beckers A, Lamberts SW. J Clin Endocrinol Metab; 2004 Apr; 89(4):1577-85. PubMed ID: 15070915 [Abstract] [Full Text] [Related]
5. Quantitative and functional expression of somatostatin receptor subtypes in human prolactinomas. Jaquet P, Ouafik L, Saveanu A, Gunz G, Fina F, Dufour H, Culler MD, Moreau JP, Enjalbert A. J Clin Endocrinol Metab; 1999 Sep; 84(9):3268-76. PubMed ID: 10487698 [Abstract] [Full Text] [Related]
6. Effects of somatostatin-14 and the receptor-specific somatostatin analogs on chromogranin A and alpha-subunit (alpha-SU) release from "clinically nonfunctioning" pituitary adenoma cells incubated in vitro. Pawlikowski M, Lawnicka H, Pisarek H, Kunert-Radek J, Radek M, Culler MD. J Physiol Pharmacol; 2007 Mar; 58(1):179-88. PubMed ID: 17440235 [Abstract] [Full Text] [Related]
7. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Neuroendocrinology; 2006 Mar; 83(3-4):258-63. PubMed ID: 17047391 [Abstract] [Full Text] [Related]
8. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro. Gruszka A, Kunert-Radek J, Radek A, Pisarek H, Taylor J, Dong JZ, Culler MD, Pawlikowski M. Life Sci; 2006 Jan 11; 78(7):689-93. PubMed ID: 16115652 [Abstract] [Full Text] [Related]
10. In vitro characterization of somatostatin receptors in the human thymus and effects of somatostatin and octreotide on cultured thymic epithelial cells. Ferone D, van Hagen PM, van Koetsveld PM, Zuijderwijk J, Mooy DM, Lichtenauer-Kaligis EG, Colao A, Bogers AJ, Lombardi G, Lamberts SW, Hofland LJ. Endocrinology; 1999 Jan 11; 140(1):373-80. PubMed ID: 9886848 [Abstract] [Full Text] [Related]
11. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions. Bertherat J, Brue T, Enjalbert A, Gunz G, Rasolonjanahary R, Warnet A, Jaquet P, Epelbaum J. J Clin Endocrinol Metab; 1992 Aug 11; 75(2):540-6. PubMed ID: 1353505 [Abstract] [Full Text] [Related]
14. In vivo and in vitro effects of octreotide, quinagolide and cabergoline in four hyperprolactinaemic acromegalics: correlation with somatostatin and dopamine D2 receptor scintigraphy. Ferone D, Pivonello R, Lastoria S, Faggiano A, Del Basso de Caro ML, Cappabianca P, Lombardi G, Colao A. Clin Endocrinol (Oxf); 2001 Apr 11; 54(4):469-77. PubMed ID: 11318782 [Abstract] [Full Text] [Related]
15. Effect of 17beta-estradiol on somatostatin receptor expression and inhibitory effects on growth hormone and prolactin release in rat pituitary cell cultures. Djordjijevic D, Zhang J, Priam M, Viollet C, Gourdji D, Kordon C, Epelbaum J. Endocrinology; 1998 May 11; 139(5):2272-7. PubMed ID: 9564833 [Abstract] [Full Text] [Related]
16. Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas. Rubinfeld H, Hadani M, Barkai G, Taylor JE, Culler MD, Shimon I. J Clin Endocrinol Metab; 2006 Jun 11; 91(6):2257-63. PubMed ID: 16595604 [Abstract] [Full Text] [Related]
20. Expression and function of somatostatin receptor subtype 1 in human growth hormone secreting pituitary tumors deriving from patients partially responsive or resistant to long-term treatment with somatostatin analogs. Matrone C, Pivonello R, Colao A, Cappabianca P, Cavallo LM, Del Basso De Caro ML, Taylor JE, Culler MD, Lombardi G, Di Renzo GF, Annunziato L. Neuroendocrinology; 2004 Mar 11; 79(3):142-8. PubMed ID: 15103227 [Abstract] [Full Text] [Related] Page: [Next] [New Search]